维帕他韦与索磷布韦/维帕他韦在肝功能不全受试者中的药代动力学与安全性
两项研究评估维帕他韦及索磷布韦/维帕他韦在肝功能不全者的药代动力学与安全性:I期研究中中度或重度肝功能不全者维帕他韦暴露与肝功能正常者相似;III期ASTRAL-4中Child-Pugh B级失代偿肝硬化患者索磷布韦暴露约升高100%但无临床相关性,结论为任何程度肝功能不全均无需调整索磷布韦/维帕他韦剂量。
要点
- Child-Pugh B或C级肝功能不全者维帕他韦暴露与肝功能正常者相似。
- Child-Pugh B级失代偿肝硬化患者索磷布韦暴露约升高100%,无临床相关性。
- 任何程度肝功能不全患者均无需调整索磷布韦/维帕他韦剂量。
核心结论
- 任何程度肝功能不全患者均无需调整索磷布韦/维帕他韦剂量。
研究设计与样本
- I期研究:丙型肝炎病毒未感染的中度或重度肝功能不全者(Child-Pugh B或C级)及人口学匹配的肝功能正常者单次口服维帕他韦100 mg。
- III期ASTRAL-4研究:Child-Pugh B级失代偿肝硬化患者随机接受索磷布韦/维帕他韦±利巴韦林12周或索磷布韦/维帕他韦24周。
主要发现
- I期研究中Child-Pugh B级(n=10)或C级(n=10)肝功能不全者维帕他韦血浆暴露(AUC)与肝功能正常者(n=13)相似。
- 无论有无任何程度肝功能不全,维帕他韦游离药物百分比相似。
- ASTRAL-4中Child-Pugh B级患者维帕他韦总体暴露(AUCtau)与ASTRAL-1人群相似。
- ASTRAL-4中Child-Pugh B级患者索磷布韦暴露较ASTRAL-1人群约升高100%,未认为有临床相关性。
临床怎么用
- 临床使用索磷布韦/维帕他韦时,无需因患者存在任何程度肝功能不全而调整剂量。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The pharmacokinetics and safety of velpatasvir, a potent pangenotypic hepatitis C virus NS5A inhibitor, were evaluated in two hepatic impairment studies: a phase I study in hepatitis C virus-uninfected subjects and a phase III study (ASTRAL-4) in hepatitis C virus-infected patients. METHODS: In the phase I study, subjects with moderate or severe hepatic impairment (Child-Pugh-Turcotte Class B or C), and demographically matched subjects with normal hepatic function received a single dose of velpatasvir 100 mg. Pharmacokinetics and safety assessments were performed, and pharmacokinetic parameters were calculated using non-compartmental methods and summarized using descriptive statistics and compared statistically by geometric least-squares mean ratios and 90% confidence intervals. In ASTRAL-4, subjects with decompensated cirrhosis (Child-Pugh-Turcotte Class B) were randomized to receive treatment with either sofosbuvir/velpatasvir ± ribavirin for 12 weeks or sofosbuvir/velpatasvir for 24 weeks. Pharmacokinetic and safety assessments were performed and pharmacokinetic parameters were calculated using a non-compartmental analysis and summarized using descriptive statistics and were compared to pharmacokinetics from ASTRAL-1 [subjects without cirrhosis or with compensated (Child-Pugh-Turcotte Class A) cirrhosis]. RESULTS: In the phase I study, plasma exposures (area under the concentration-time curve) were similar in subjects with Child-Pugh-Turcotte Class B (n = 10) or Child-Pugh-Turcotte Class C hepatic impairment (n = 10) compared with normal hepatic function (n = 13). Percent free velpatasvir was similar in subjects without or with any degree of hepatic impairment. In the phase III study, velpatasvir overall exposure (area under the concentration-time curve over the 24-h dosing interval; AUCtau) was similar and sofosbuvir exposures were higher (~ 100%) for patients with Child-Pugh-Turcotte Class B hepatic impairment compared with the ASTRAL-1 population, which was not considered clinically relevant. CONCLUSIONS: No sofosbuvir/velpatasvir dose modification is warranted for patients with any degree of hepatic impairment.
引用
- Mogalian E, Brainard DM, Osinusi A, et al. Pharmacokinetics and Safety of Velpatasvir and Sofosbuvir/Velpatasvir in Subjects with Hepatic Impairment. Clin Pharmacokinet. 2018. PMID: 29520729. doi:10.1007/s40262-018-0645-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。